The use of dabigatran as a treatment to prevent strokes is not associated with greater risks of bleeding than warfarin, according to the FDA's MedWatch adverse event reporting system. However, some critics in the medical community say dabigatran's risks may be exacerbated by the lack of an approved antidote to its anticoagulant effects.